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Abstract
In rodents, in utero exposure to exogenous estrogens including diethylstilboestrol (DES) results in major suppression of
steroidogenesis in fetal testes. Whether similar effects occur in the human fetal testis is equivocal. Based on the results of
the rodent studies, we hypothesised that exposure of human fetal testes to DES would result in a reduction in testosterone
production. We show, using a xenograft approach, that testosterone production is not reduced in human fetal testis
following DES exposure. Human fetal testes (15–19 weeks’ gestation, n = 6) were xenografted into castrate male nude mice
which were then treated for 35 days with vehicle or 100 mg/kg DES three times a week. For comparison, similar treatment
was applied to pregnant rats from e13.5–e20.5 and effects on fetal testes evaluated at e21.5. Xenograft testosterone
production was assessed by measuring host seminal vesicle (SV) weights as an indirect measure over the entire grafting
period, and single measurement of serum testosterone at termination. Human fetal testis xenografts showed similar survival
in DES and vehicle-exposed hosts. SV weight (44.3 v 26.6 mg, p = 0.01) was significantly increased in DES compared to
vehicle-exposed hosts, respectively, indicating an overall increase in xenograft testosterone production over the grafting
period, whilst serum testosterone at termination was unchanged. In contrast intra-testicular testosterone levels were
reduced by 89%, in fetal rats exposed to DES. In rats, DES effects are mediated via Estrogen Receptor a (ESR1). We
determined ESR1 protein and mRNA expression in human and rat fetal testis. ESR1 was expressed in rat, but not in human,
fetal Leydig cells. We conclude that human fetal testis exposure to DES does not impair testosterone production as it does
in rats, probably because ESR1 is not expressed in human fetal Leydig cells. This indicates that DES exposure is likely to pose
minimal risk to masculinization of the human fetus.
Citation: Mitchell RT, Sharpe RM, Anderson RA, McKinnell C, Macpherson S, et al. (2013) Diethylstilboestrol Exposure Does Not Reduce Testosterone Production
in Human Fetal Testis Xenografts. PLoS ONE 8(4): e61726. doi:10.1371/journal.pone.0061726
Editor: Jean-Marc A. Lobaccaro, Clermont Universite´, France
Received January 16, 2013; Accepted March 11, 2013; Published April 19, 2013
Copyright:  2013 Mitchell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported in part by Grants G1100358 (RMS) and G1100357 (RAA) from the Medical Research Council and research awards from the
British Society for Paediatric Endocrinology and Diabetes, and from the Academy of Medical Sciences (both RTM). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rod.mitchell@ed.ac.uk
Introduction
Male reproductive disorders (cryptorchidism, hypospadias,
testicular germ cell cancer, low sperm counts) are common and
some have increased significantly in incidence in recent decades,
raising concern about the role that lifestyle/environmental factors
play in their etiology [1]. It has been proposed that these disorders
are components of a ‘Testicular Dysgenesis Syndrome’ (TDS) with
a common origin in fetal life [2]. Suppression of testosterone
production resulting in abnormal testis development/function
during fetal life has been implicated in the development of the
TDS disorders [1,3,4,5]. What remains unclear is what lifestyle/
environmental factors could affect human fetal testis develop-
ment/function and give rise to these disorders.
Twenty years ago the so-called ‘estrogen hypothesis’ was
proposed which suggested that the increasing incidence of
reproductive abnormalities in the human male may be related to
increased estrogen exposure in [6]. This hypothesis was supported
by a number of studies in pregnant rats exposed to the synthetic
estrogen DES and by some epidemiological data in male offspring
of mothers exposed in utero to DES [2]. Male offspring of rats
exposed in utero to DES demonstrated gross suppression of
testosterone [7,8]. Studies in estrogen receptor-1 knockout
(ERKO) mice have shown that the effects of DES are mostly
mediated through classical estrogen signalling pathways involving
ESR1 [9].
During the 1940’s–1970’s DES (,60–70 mg/kg/d) was admin-
istered to pregnant women to prevent miscarriage and was
reported to result in an increased incidence of reproductive tract
abnormalities in both male and female offspring [10,11].
However, other studies of the consequences of exogenous estrogen
exposure in human pregnancy, including detailed meta-analyses,
have largely failed to provide support for the estrogen hypothesis-
TDS relationship in humans [12,13,14,15]. Moreover, some
studies have indicated that ESR1 is not expressed in human fetal
Leydig cells [16,17].
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In view of the previous lack of a human relevant system in
which to investigate the effects of in utero exposure to estrogens,
there remains uncertainty about the risk that environmental
estrogens pose to masculinization of the human male [2]. We
hypothesised that exposure of human fetal testis to DES results in a
reduction in testosterone production as it does in rats and mice.
We have validated a xenograft system to determine the effects of
exposure to environmental chemicals on the human fetal testis
[18]. The system involves grafting human fetal testis tissue into
immune-compromised castrate mice, where it grows and develops
normally for prolonged periods (6+ weeks) [19]. Treatment with
hCG during the grafting period to mimic normal in utero exposure,
maintains Leydig cell steroidogenesis and thus stimulates growth of
the host seminal vesicle, reflecting testosterone production from
the xenografts over the duration of the grafting period [19]. The
xenograft model more effectively recapitulates the normal
situation in pregnancy, without the reservations about in vitro
and indirect approaches and as a result has the potential to
provide a more ‘physiological’ system in which to evaluate the
effects of exposure to estrogens on human fetal testis testosterone
production. This was the aim of the present studies.
Methods
Ethics Statement
For all studies, animals were treated humanely and with regard
for alleviation of suffering. Studies were performed according to
the Animal (Scientific Procedures) Act 1986 following specific
approval by the UK Home Office. Studies were conducted under
an approved Project Licence (PPL 60/3914) following review by
the University of Edinburgh Animal Research Ethics Committee.
In order to obtain human fetal testes, women undergoing elective
termination gave written consent in accordance with UK national
guidelines [20], and ethical approval for this study was obtained
from the Lothian Research Ethics Committee (LREC - 08/
S1101/1).
Human Fetal Testes and the Xenografting Procedure
Second trimester (15–19 weeks, n = 6) human fetal testes were
obtained following elective termination of pregnancy. No termi-
nations were due to fetal abnormalities. A small portion of each
testis was fixed as a pre-graft control, whilst the remainder was
placed immediately into ice-cold media containing Liebowitz L-15
with glutamine, 10% fetal bovine serum, 1% penicillin/strepto-
mycin and 1% non-essential amino acids (all Sigma, Poole, UK)
for xenografting. Male CD1 nude mice (aged 4–6 weeks, n = 30;
Charles River UK, Margate, England) were anesthetised by
inhalation of isofluorane, and castrated. After a recovery period of
1–2 weeks, small pieces (1 mm3 approx.) of donor testis tissue were
inserted subcutaneously under the dorsal skin using a 13G cancer
implant needle (Popper and Sons, New York, US). Grafts (5–6 per
mouse) were inserted on either side of the midline. Mice were
housed individually and received analgesia (Carprofen; Pfizer,
New York, USA) and antibiotics (Enrofloxacin; Bayer, Germany)
in the drinking water for 5 days post-surgery. In general, 4–6 mice
were xenografted with tissue from each fetus and half of these mice
were then allocated to vehicle+hCG treatment and half to
DES+hCG treatment.
Treatments of Host Mice
Host mice receiving xenografts from human fetal testis tissue
were injected subcutaneously every 72 h with 20 IU hCG
(Pregnyl, Organon Laboratories, Cambridge, UK) in 0.9% (w/v)
saline containing 1% (v/v) fetal bovine serum, which has been
shown to be required to maintain testosterone production by the
xenografts and reflects the high levels of hCG in human pregnancy
[18]. Host mice were treated by subcutaneous injection with either
vehicle (corn oil) or 100 mg/kg DES (Sigma, Poole, Dorset) diluted
in corn oil. In xenografted host mice, all treatments commenced 7
days after grafting and continued 3 times a week until the end of
the grafting period (,5 weeks). Ungrafted castrate mice (n = 6)
were also treated with either DES or vehicle as above in order to
provide baselines for seminal vesicles and testosterone and to
ensure that any effects of the treatment were specific to the human
fetal testis xenografts. The dose and treatment regimen for DES
was based on studies by ourselves (see below and [8]) and others
[7], which showed major suppression of intratesticular testosterone
in fetal rats and mice using this regimen.
Retrieval of Xenografts
Xenografts of human fetal testis were retrieved after 6 weeks.
Host mice were killed by cervical dislocation and blood obtained
by cardiac puncture for measurement of testosterone. Seminal
vesicles were removed and weighed and xenografts were retrieved,
weighed and fixed for 2 h in Bouin’s fixative, before being
transferred to 70% (v/v) ethanol and then processed into paraffin
blocks.
Fetal Rat Studies
Wistar rats were maintained according to UK Home Office
guidelines and were fed a soy-free breeding diet (RM3(E) soya free;
SDS, Dundee, Scotland). Housing conditions were carefully
controlled (lights on at 0700, off at 1900 h, temperature 19–
21uC, GOLD shavings and LITASPEN standard bedding (SPPS,
Argenteuil, France)). Time-mated female rats were injected
subcutaneously with DES (Sigma-Aldrich) at a dose of 100 mg/
kg in 1 ml/kg corn oil on e13.5, e15.5, e17.5, e19.5 and e20.5. Rat
dams were killed on e21.5 by inhalation of CO2 followed by
cervical dislocation. Fetuses were removed, decapitated and placed
in ice cold phosphate buffered saline (PBS; Sigma-Aldrich). Testes
were microdissected, and fixed in Bouin’s fixative for 1 h at room
temperature or snap frozen and stored at 270uC for gene
expression analysis or determination of intratesticular testosterone
(ITT). For the latter, the testis was homogenized and its total
testosterone content determined after extraction and measurement
as described below. Bouin’s-fixed tissues were processed and
embedded in paraffin wax, and 5 mm sections were cut and used
for immunohistochemistry.
Testosterone Assay
Xenograft host serum testosterone levels and rat fetal intra-
testicular testosterone levels were measured at termination by
competitive radioimmunoassay using an in-house radioimmuno-
assay method described previously [21]. The method used
radiolabelled testosterone (I125, MP Biomedicals, UK) and a
rabbit primary antibody (1:600,000; AMS Biotech, Abingdon,
UK). Residual I125 was measured with a gamma counter
(WIZARD 1470, Perkin Elmer, Turku, Finland) and testosterone
levels were expressed as ng/ml (human xenografts) or pg/testis (rat
fetal testis). All samples were analysed in a single assay, the
detection limit for which was 45 pg/ml and the intra-assay CV
was 8%.
Immunohistochemistry
Immunohistochemistry was performed on human fetal testis
tissue (ungrafted, n= 5; vehicle-exposed grafts, n = 3; DES-
exposed grafts, n = 3), human adult endometrium obtained at
DES Exposure in the Human Fetal Testis
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61726
endometrial biopsy (n = 1) and rat fetal testis (n = 3) as previously
described [22]. Sections (5 mm) were subjected to heat induced
antigen retrieval in 0.01 M citrate buffer (pH 6), and endogenous
peroxidase blocked with 3% (v/v) H2O2 in methanol for 30 min.
Endogenous biotin was blocked using an avidin/biotin blocking kit
(Vector Laboratories Inc., Peterborough, UK), according to
manufacturer’s instructions. Sections were incubated in normal
rabbit serum diluted 1:5 with TBS containing 5% (w/v) BSA for
30 min. Sections were incubated overnight with primary antibody
(ESR1, mouse anti-human 1:50; Vector Laboratories, Peterbor-
ough, UK) diluted in serum at 4uC in a humidified chamber and
then incubated for 30 min with a biotinylated secondary antibody
(rabbit anti-mouse; DAKO, Ely, Cambridgeshire, UK) at 1:500,
diluted in normal serum/TBS/BSA, followed by 30 min incuba-
tion with Streptavidin-HRP (DAKO) at 1:1000, diluted in TBS.
Visualization was performed using 3,3-diaminobenzidine tetra-
hydrochloride (DAB, DAKO) and sections were counterstained
with hematoxylin before mounting in Pertex mounting medium
(CellPath plc, Hemel Hempstead, UK). Negative controls were
sections in which the primary antibody was replaced with the
appropriate normal serum/TBS/BSA. Images were captured as
previously described [22].
Gene Expression Analysis
For quantitative analysis of gene expression by RT-PCR, total
RNA was extracted from pre-graft control human fetal testis
samples (n = 3) and adult human endometrium obtained at
endometrial biopsy (n = 1) using the RNeasy Micro Kit with on-
column DNase digestion (Qiagen, UK). Random hexamer primed
cDNA was prepared using the Applied Biosystems TaqmanTM RT
kit (Applied Biosystems, CA). Quantitative real time PCR (qRT-
PCR) was performed on the ABI Prism Sequence Detection
System (Applied Biosystems). Expression of human ESR1 was
determined using the Roche Universal Probe Library (human
ESR1 forward primer 59-AACCAGTGCACCATTGATAAAA-
39, reverse primer 59-TCCTCTTCGGTCTTTTCGTATC-39,
probe number 69 Cat no. 04688686001; Roche Applied Sciences,
Burgess Hill, UK). The expression level of human ESR1 was
corrected using 18S ribosomal RNA as internal control (Applied
Biosystems Cat no. 4308329). All samples were performed in
triplicate for 3 separate fetuses (14–19 weeks old) and a relative
comparison was made to human adult endometrium for ESR1.
Statistics
Statistical analysis was performed using Graphpad Prism 5
software (La Jolla, California USA). Results were analysed using
paired t-test with Bonferroni post-hoc test. For human fetal testis
xenografts data were also analysed by two-way ANOVA to take
account of the variation between replicate grafts (ie grafts from the
same fetus but into separate hosts that then receive comparable
treatment) and between individual fetuses. Data for fetal ITT and
mRNA levels were log transformed prior to analysis to normalise
variances.
Results
Xenograft Retrieval from Vehicle- and DES-exposed Mice
At the end of the xenografting period, grafts were easily
identified and retrieved from the subcutaneous tissue. The
majority of the 182 grafts were retrieved at the end of the grafting
period with no difference between vehicle or DES-exposed groups
(78 v 70% retrieval, p.0.05; Fig. 1A). Total recovered graft
weight per mouse was almost identical for vehicle- and DES-
exposed groups (6.98 v 6.99 mg; Fig. 1B).
Effect of Exposure to DES on Testosterone Production by
Xenografts
To determine the effect of exposure to DES on testosterone
production from the xenografts, serum testosterone and seminal
vesicle weight were measured in the host animals. Unexpectedly,
seminal vesicle weight was significantly increased in the DES-
exposed hosts compared to vehicle (26.6 v 44.3 mg, p = 0.002;
Fig. 2A). Serum testosterone levels at termination were not
significantly different in the DES-exposed hosts compared to
vehicle (0.33 v 0.51 ng/ml, p.0.05; Fig. 2B). There was variation
between individual fetuses for baseline seminal vesicle weight
(Fig. 2C) and serum testosterone (Fig. 2D) and therefore two-way
ANOVA was performed to take into account this variation. In
order to ensure that these results were due to effects on the
xenografts and not the host animal, we measured seminal vesicle
weight and serum testosterone in ungrafted mice. There was no
effect of DES on seminal vesicle weight or serum testosterone in
ungrafted control mice (Fig. 2A,B)).
To compare the results obtained for the human fetal testis with
those in the rat, we exposed pregnant rats to DES (n= 4) or vehicle
(n = 3) from e13.5– e20.5 and intratesticular testosterone was
determined at e21.5; because of the small blood volume of e21.5
fetuses it was not feasible to measure blood levels of testosterone.
There was a significant overall decrease (89%) in intratesticular
testosterone in DES-exposed fetal rat testes compared to vehicle-
exposed controls (260.2 v 29.1 pg/testis, p,0.001; Fig. 3). This
finding was consistent between litters with a significant reduction
in ITT in all DES-exposed litters compared with controls.
ESR1 Expression in the Fetal Testis of Human and Rat
The effects of DES in rodents have been shown to be mediated
through ESR1 signalling [9]. We compared ESR1 expression in
control fetal human testis (n = 3) with that of rat. ESR1 mRNA was
barely detectable in the human fetal testis (Fig. 4A). Human fetal
testis exhibited 175-fold lower mRNA expression compared with
human adult endometrium. Immunoexpression of ESR1 protein
was not detected in the Leydig cells of the human fetal testis
(Fig. 4B). In addition no expression was identified in either vehicle-
exposed or DES-exposed xenografts (not shown). In contrast, in
rats, there was clear immunoexpression in fetal rat Leydig cells
(Fig. 4C). As a positive control ESR1 protein expression was
detected in the human endometrium demonstrating the specificity
of this antibody in human tissue (Fig. 4B, inset).
Discussion
The original ‘estrogen hypothesis’ [6] proposed that the increase
in male reproductive abnormalities (testis cancer, cryptorchidism,
hypospadias, low sperm counts) over recent decades might have
occurred because of increased exposure to estrogens from various
potential sources. Subsequent studies in rats and mice that
involved manipulation of fetal estrogen exposure confirmed that
supranormal estrogen exposure could act on steroidogenic
pathways that can underlie male reproductive disorders [2,7,8].
However, direct evidence of an effect of DES on the human fetal
testis has so far been lacking. The present studies aimed to
determine the effect of exposure to DES on testosterone
production by the human fetal testis using a xenograft approach,
shown to recapitulate normal human fetal testis development and
to be a useful model in which to determine the effects of exposure
to proposed ‘endocrine disruptors’ [18,19].
The present studies have demonstrated that exposure to DES,
given at a dose in the equivalent range to previous clinical use
(100 mg/kg three times a week), does not lead to any detectable
DES Exposure in the Human Fetal Testis
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reduction in testosterone production/action by second trimester
human fetal testis xenografts. In fact we found a significant
increase in seminal vesicle weight in xenografted host mice
exposed to DES, indicating an increase in overall testosterone
production from the xenografts during the grafting period,
although there was no significant difference in single measure-
ments of serum testosterone concentration at the time of graft
recovery. The increase in seminal vesicle weight is unexplained
and requires further study. In non-castrate adult mice exposed to
DES, seminal vesicle weights are reported to decrease [23]. We
have ruled out the possibility that a direct action of DES on the
mouse seminal vesicles is causing the increase in seminal vesicle
weight by exposing ungrafted castrate mice to DES and found no
difference, therefore the increase in seminal vesicle weight in
xenografted mice must involve the human fetal testis. Our results
do not rule out the possibility that DES can affect testosterone
Figure 1. Graft survival and total graft weight of human fetal testis xenografts recovered from host mice exposed to either vehicle
or DES at six weeks after xenografting. A) Graft survival (%). B) Total graft weight (mg). Data analysed by unpaired t-test; Mean6 SEM for n = 15,
p.0.05.
doi:10.1371/journal.pone.0061726.g001
Figure 2. Effect of exposure to DES on testosterone production by human fetal testis xenografts. Seminal vesicle weight A) and serum
testosterone B) in ungrafted (n = 6) and xenografted (n = 15) mice. Mean 6 SEM. Bars with letters in common are not significantly different. Data
analysed by unpaired t-test. Base-line variation in seminal vesicle weight C) and serum testosterone D) for host mice xenografted with individual
fetuses (n = 6). Mean 6 SEM. Data analysed by two-way ANOVA.
doi:10.1371/journal.pone.0061726.g002
DES Exposure in the Human Fetal Testis
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production via indirect mechanisms that involve effects on the
placenta or the fetal brain, however we consider it unlikely that the
increased testosterone production is being stimulated centrally via
the hypothalamo-pituitary-gonadal axis, given that high gonado-
trophin levels induced by castration of the host animal have been
shown to result in low (baseline) levels of testosterone production
from the xenografts in the absence of exogenous hCG [19].
DES has been shown to exert its major adverse effects mainly
through classical estrogen receptor signalling, in particular via
ESR1 [24,25]. In a mouse fetal testis organ culture system the
reduction in testosterone production that occurred following DES
exposure in wild-type testes did not occur in ESR1 deficient mice
[24]. Given that the effects in mice are mediated by ESR1 we
examined the expression of ESR1 in the human fetal testis and did
not detect expression of this protein in fetal Leydig cells, consistent
with previous findings [16,17]. However, we confirmed that ESR1
expression was present in fetal rat Leydig cells; this difference
offers a straightforward explanation for the differential sensitivity
of fetal Leydig cells in terms of testosterone production following
DES-exposure in rodents versus the human. It also indicates that
any stimulatory effects on testosterone production in human fetal
testes are likely to be mediated via an alternative estrogen
signalling pathway. This is supported by evidence for actions of
DES involving alternative pathways, such as the estrogen-related
receptors [26] and/or the orphan receptor Nr0b2 [27].
We confirmed that exposure of the fetal rat testis to the same
DES treatment regimen resulted in ,90% reduction in fetal intra-
testicular testosterone [7,8]. As a reduction in testosterone
production by the fetal testis is widely viewed as being the most
likely mechanism for the origin of TDS disorders, the present
findings suggest that exposure of the human fetal testis to
estrogenic environmental chemicals, or indeed to any supranormal
estrogen exposure, is unlikely to induce such effects, at least where
this is mediated via ESR1.
Our findings are consistent with a recent study that used in vitro
culture of human 1st trimester fetal testes, which also showed that
testosterone production was not reduced by exposure to DES [28].
The limitations of the in vitro approach, such as the short duration
of exposure and decline in tissue integrity, are addressed by the
current approach which permits long term treatments and
maintenance of tissue integrity in addition to exposure via the
circulation of the host animal [19].
From the 1940’s until the early 1970’s DES (,60–70 mg/kg
daily from gestational weeks 8–14, increasing by 5 mg/week
thereafter), was prescribed to pregnant mothers for its proposed
role in reducing spontaneous miscarriage and pre-term labour
[10,29]. It was subsequently shown that DES exposure in utero had
a causal role in the development of vaginal malignancy [30]. It has
also been reported that DES-exposure is associated with structural
abnormalities of the male reproductive tract including epididymal
cysts, microphallus and testicular hypoplasia (Reviewed in [29]).
However there is conflicting evidence regarding DES and the
disorders that comprise TDS. Several studies report an increased
risk of testicular cancer following prenatal exposure to exogenous
estrogen [31,32,33,34,35]. Of the two studies which specifically
investigated DES effects, one found no increased risk [36]. All the
other studies reported increased risks that were not statistically
significant [31,32,33,34,35]. To date there remains no conclusive
evidence of an increased risk of testicular cancer following prenatal
DES exposure [6,14,29]. Hypospadias has been reported to be
Figure 3. Effect of exposure to DES from e13.5–e20.5 on
intratesticular testosterone (ITT) at e21.5 in fetal rat testes.
Data is presented as litter means (unpaired t-test, p = 0.004).
doi:10.1371/journal.pone.0061726.g003
Figure 4. ESR1 expression in human fetal testis and endometrium. A) Relative ESR1 mRNA expression in adult human endometrium
compared with human fetal testis (n = 3). w=weeks. Note: data presented on a log-scale. ESR1 protein expression in B) a 20 week gestation ungrafted
human fetal testis and human endometrium (positive control; inset.) and C) e21.5 rat fetal testis. SC= seminiferous cords, arrows indicate Leydig cells.
Original magnification 206. Scale bar = 50 mm.
doi:10.1371/journal.pone.0061726.g004
DES Exposure in the Human Fetal Testis
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more prevalent in DES exposed males [37], however these data
related to urethral abnormalities rather that hypospadias per se
[38]. A recent meta-analysis reported a small increased risk of
hypospadias in DES/estrogen exposed males [14]. However, any
such effect may perhaps result from direct effects on the
developing penis [39] [40], rather than as the consequence of
reduced testosterone production by the fetal human testis. In
addition the available epidemiological evidence suggests that
human exposure in utero to estrogens other than DES, such as
environmental estrogens and those in the oral contraceptive pill do
not result in increased risk of TDS disorders in male offspring
[14,41].
A more recent study has shown an increased risk of
cryptorchidism in males exposed in utero to DES, although this
was associated with initial exposure before the 11th week of
gestation with no significant effect in those initially exposed after
11 weeks [15]. Rat studies have demonstrated that testosterone
production/action within a discrete masculinization programming
window (MPW), is responsible for programming subsequent
normal male reproductive development, and TDS disorders may
only result if there is a reduction in androgen production/action in
this period [42]; the present studies investigated effects of DES
exposure on the human testis from 15 weeks of gestation, which is
after the postulated MPW [42]. It is therefore possible that this
could explain the lack of effect of DES on testosterone production.
However, the effects of DES on testosterone production by the
fetal testis in rats occur beyond the MPW, as shown in the present
study (e21.5). In addition, DES exposure of first trimester human
fetal testes in vitro had no effect on testosterone production [28].
Taken together, it seems unlikely that our present negative
findings regarding DES effects are simply due to the gestational
age of the fetus. An alternative mechanism for the reported
increased incidence of cryptorchidism could be via effects on Insl3,
a key factor in testicular descent in rodents [43,44]. In humans,
Insl3 is believed to be important during early testicular descent
between 8–15 weeks gestation [45]. Further studies to investigate
the effects of DES on Insl3 in first trimester human fetal testis
would address this.
Conclusion
In rodents, exposure to DES in utero results in disorders of the
reproductive tract mediated by a reduction in testosterone
production. It has been postulated that similar effects occur in
humans. Using a xenograft approach, we have demonstrated that
exposure to DES does not result in a reduction in production of
testosterone by the human fetal testis. This lack of effect on
testosterone may be due to the lack of ESR1 in human fetal Leydig
cells, in contrast to rodents. The findings highlight important
species differences between humans and rodents, with implications
for assessing the risk to human health that fetal exposure to
environmental estrogens might pose.
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